KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sarepta Therapeutics (SRPT) Equity Ratio (2016 - 2025)

Sarepta Therapeutics has reported Equity Ratio over the past 16 years, most recently at 0.34 for Q4 2025.

  • For Q4 2025, Equity Ratio fell 11.67% year-over-year to 0.34; the TTM value through Dec 2025 reached 0.34, down 11.67%, while the annual FY2025 figure was 0.34, 11.67% down from the prior year.
  • Equity Ratio for Q4 2025 was 0.34 at Sarepta Therapeutics, down from 0.38 in the prior quarter.
  • Over five years, Equity Ratio peaked at 0.39 in Q4 2024 and troughed at 0.12 in Q4 2022.
  • A 5-year average of 0.27 and a median of 0.27 in 2022 define the central range for Equity Ratio.
  • Biggest five-year swings in Equity Ratio: plummeted 58.26% in 2022 and later skyrocketed 113.92% in 2023.
  • Year by year, Equity Ratio stood at 0.29 in 2021, then tumbled by 58.26% to 0.12 in 2022, then soared by 113.92% to 0.26 in 2023, then soared by 46.44% to 0.39 in 2024, then decreased by 11.67% to 0.34 in 2025.
  • Business Quant data shows Equity Ratio for SRPT at 0.34 in Q4 2025, 0.38 in Q3 2025, and 0.37 in Q2 2025.